spectrum® PHARMACY PRODUCTS

800.370.6231
SpectrumRx.com

SUGGESTED FORMULA

Cantharidin 1% / Podophyllum Resin 5% and Salicylic Acid 20% in Topical Escharotic Suspension

Version number: 1.0

Volume: 100mL

Cantharidin	1gm
Podophyllum Resin, USP (PO105)	5gm
Salicylic Acid, USP (SA130)	20gm
Dehydrated Alcohol, 200 Proof, Undenatured USP (ET107)	10mL
Benzoin, Compounding Tincture, USP	Q.S. 100mL

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Place the Cantharidin powder in a disposable mortar and add the dehydrated alcohol; triturate gently and permit to sit covered under the hood until the powder is saturated.
4. Add the Podophyllum powder to the Cantharidin and alcohol mixture and permit to be wetted with mortar covered
5. In a glass graduated bottle, dissolve the Salicylic Acid in 60mL of compound tincture of benzoin and permit dissolution to occur with bottle capped.
6. Add the Cantharidin and Podophyllum mixture to the glass bottle quantitatively washing the disposable mortar with additional compound tincture of Benzoin

7 Bring to volume with compound tincture of Benzoin, cap bottle and shake. Permit the preparation to “rest” for two hours and recheck for homogeneity.

8. Package in glass and label. Contain all disposable mixing equipment and discard appropriately.
9. Suggested Quality Assessments – follow pharmacy SOPs:
    a. Weight to Volume calculation
    b. Color
    c. Pourability
    d. Settling
    e. Resuspendability

***For application in physician's office only. Not to be applied by the patient or the patient's caregiver**

Store in air tight amber glass containers at room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned according to the current USP <795> Standards

*Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.
9/19 JD

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com